Corporate Issues Dog Ex-Glaxo CEO's Bid For Senate

28 April 1996

Former Glaxo USA chief executive Charles Sanders faces his first political hurdle on his way to a US Senate seat in the May 7 North Carolina Democratic primary. As with other businessmen who are now entering politics, the opposition is attacking his business practices.

His opponent, Harvey Gantt, has attacked Glaxo's pricing policies and a loophole in the General Agreement on Tariffs and Trade legislation which, says Mr Gantt, will make Glaxo billions. And the state's sitting Senator, long-time conservative Republican Jesse Helms, has aired a television ad taking issue with Glaxo's policy of extending medical benefits to the domestic partners of unmarried employees, including homosexuals.

Mr Sanders, who the Wall Street Journal reports has already lent his campaign about $1 million from his own funds, is calling for a higher minimum wage and investment in education, as are most businessmen recently entering politics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight